Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Summit Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
SMMT
Nasdaq
2836
www.smmttx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Summit Therapeutics Inc.
FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug
- Nov 16th, 2026 6:23 am
Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
- Nov 16th, 2026 5:16 am
FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
- Nov 16th, 2026 3:09 am
Summit Therapeutics Says FDA Rejects Ivonescimab Application for Lung Cancer Treatment; Shares Fall Pre-Bell
- Nov 16th, 2026 2:39 am
Three FDA Decisions Loom After Summit’s Rejection — Capricor, Savara, Alzheimer’s Data Top Biotech’s Watchlist
- Nov 15th, 2026 7:25 pm
SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
- Nov 15th, 2026 6:49 pm
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- Nov 15th, 2026 5:00 am
Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?
- Nov 10th, 2026 6:55 am
Summit Therapeutics (SMMT) Stock Looks Richly Priced On Its 7x Run
- Nov 9th, 2026 5:21 pm
FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
- Nov 9th, 2026 3:23 am
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage
- Nov 8th, 2026 6:16 pm
SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus
- Nov 5th, 2026 4:37 am
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
- Nov 4th, 2026 2:36 pm
The U.S. Stocks Quietly Winning the Chinese Drug Boom
- Nov 3rd, 2026 8:26 am
Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI Deal
- Oct 30th, 2026 3:08 pm
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth
- Oct 30th, 2026 7:21 am
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
- Oct 26th, 2026 10:05 am
Lunit and Summit to evaluate pathology platform for tumour analysis
- Oct 26th, 2026 5:00 am
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
- Oct 25th, 2026 9:52 am
Scroll